SignalFDA/Bio

ALLOGENE THERAPEUTICS: IS THE MARKET LOOKING AT CAR-T PERSISTENCE THE WRONG WAY? - SEEKINGALPHA

CAR-T persistence debate challenges market assumptions, driving high investor interest.

What changed

CAR-T persistence debate challenges market assumptions, driving high investor interest.

Why it matters

CAR-T persistence debate challenges market assumptions, driving high investor interest. — impact context not separately stored; see What changed.

Sources